Browsing by title
Now showing items 4101-4120 of 4688
-
Targeting HOX/PBX dimers in cancer.
(IMPACT JOURNALS LLC, 2017-05-09)The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also ... -
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
(OXFORD UNIV PRESS INC, 2018-01-01)Oxygen deprivation (hypoxia) in non-small cell lung cancer (NSCLC) is an important factor in treatment resistance and poor survival. Hypoxia is an attractive therapeutic target, particularly in the context of radiotherapy, ... -
Targeting molecular addictions in cancer.
(NATURE PUBLISHING GROUP, 2014-11-25)Cancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis ... -
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
(NATURE PORTFOLIO, 2023-11-30)Inflammation is a hallmark of cancer1. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across ... -
Targeting NaPi2b in ovarian cancer.
(ELSEVIER SCI LTD, 2023-01-01)Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment ... -
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.
(2016-11)Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified ... -
Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.
(ELSEVIER SCIENCE INC, 2017-07-01) -
Targeting radioresistance and replication fork stability in prostate cancer.
(AMER SOC CLINICAL INVESTIGATION INC, 2022-05-09)The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein ... -
Targeting RIPK1 ubiquitylation to promote anti-tumour immunity
(Institute of Cancer Research (University Of London), 2019-11-30)Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ... -
Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex.
(ROYAL SOC CHEMISTRY, 2017-05-04)Proteins typically carry out their biological functions as multi-protein complexes, which can significantly affect the affinity of small-molecule inhibitors. HSP70 is an important target in oncology, so to study its chemical ... -
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
(ELSEVIER, 2021-05-01)BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial ... -
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.
(AMER ASSOC CANCER RESEARCH, 2017-11-01)Thousand-and-one amino acid kinases (TAOK) 1 and 2 are activated catalytically during mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize a compound that inhibits TAOK1 and ... -
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
(BMJ PUBLISHING GROUP, 2024-02-27)BACKGROUND: Targeting of solid cancers with chimeric antigen receptor (CAR)-T cells is limited by the lack of suitable tumor-specific antigens and the immunosuppressive, desmoplastic tumor microenvironment that impedes ... -
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
(MDPI, 2021-05-10)Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ... -
Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside.
(SOC NUCLEAR MEDICINE INC, 2016-07-01) -
Targeting the inflammatory response in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2024-05-20)Prostate cancer is a leading cause of male cancer mortality. Despite inflammation being implicated in prostate cancer initiation and progression, patient outcomes have been minimally impacted by immunotherapies that have ... -
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.
(MDPI, 2021-12-23)Despite major improvements in the management of advanced prostate cancer over the last 20 years, the disease remains invariably fatal, and new effective therapies are required. The development of novel hormonal agents and ... -
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-05-01)Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional ... -
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand ... -
Targeting the PI3-kinase pathway in triple-negative breast cancer.
(OXFORD UNIV PRESS, 2019-05-03)Triple-negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the phosphoinositide 3 (PI3)-kinase and AKT signalling pathway is one ...